Full Press Release Here

This communication is intended to inform all interested parties about several important changes the European Medicines Agency will be introducing shortly

New visual identity

On 8 December 2009, The EMEA will officially launch our new visual identity, comprising a new logo, new colour chart, new typography and rebranded materials based on these elements. The EMEA are giving you advance notice of this so that you are not surprised when you start to see new documents and other materials emerging from the Agency that do not bear the familiar ‘EMEA’ logo. The EMEA have created the new visual identity as part of a wider effort to improve the quality and consistency of our communications with partners, stakeholders and the public. The main benefit is that our communications materials will now be based on professionally designed templates, and have a more harmonised look and feel than our current materials. The cornerstone of their new identity is a new logo they have created that reflects more accurately the nature and character of the Agency, which has evolved significantly in the 15 years since it, and the original logo, were created. Please visit there public website on 8 December for further details about our new visual identity and materials.

Still the European Medicines Agency, but no longer ‘the EMEA’ – and not ‘the EMA’
either

While you may be familiar with us as ‘the EMEA’, many of their partners and stakeholders over the years have told tjhem they find the acronym confusing, firstly because it does not accurately reflect their name (“What does the second ‘e’ stand for?”) and secondly because it is an acronym widely used in the business community to mean ‘Europe, Middle East and Africa’, which can cause some confusion. Since it is important to them that they communicate clear and unambiguous messages about who they are, they have decided that they will no longer be using the EMEA acronym in their communications, and it does not feature in there new logo. Please note that they will not be calling ourselves ‘the EMA’ either. Although this may seem a more obvious acronym, it is not one that feels right for them yet. They may reconsider our position at a later stage, if ‘EMA’ evolves naturally into a commonly accepted and widely used shorthand for our organisation. Until then, however, they will be using only their full name (or ‘the Agency’, for short) in our communications. (For technical reasons, they need to use some kind of abbreviation in our document references and our website and e-mail addresses. They will exceptionally use ‘EMA’ in these defined cases.)

New ‘ema.europa.eu’ address for their website and e-mails

On 8 December 2009, all Agency website and e-mail addresses will change from ‘emea.europa.eu’ to ‘ema.europa.eu’, as a consequence of there decision to discontinue our use of the acronym ‘EMEA’. From that date onwards, the address of our public website will be www.ema.europa.eu and our e-mail addresses will take the form name.surname@ema.europa.eu Please update your website bookmarks, address books, contacts databases and other resources accordingly.

New organisation chart

Over the past three months, they have been implementing a series of changes to our internal organisation, aimed at improving the functioning of the Agency and the way in which they deliver their core tasks. The new structure and allocation of responsibilities will be made public on 8 December 2009. Key changes relate to the two units responsible for medicines for human use that have been re-formed and re-named to become ‘Human Medicines Development and Evaluation’ (formerly ‘Pre-authorisation Unit’) and ‘Patient Health Protection’ (formerly ‘Post-authorisation Unit’). Staff members dealing with veterinary medicines have been re-grouped in one single sector responsible for all areas of veterinary medicines. In addition, a single sector has also been formed to manage product data and documentation related to applications for both human and veterinary medicines. Overall, the changes to our organisational structure will ensure more accountability at various management levels, and will allow them to achieve greater efficiency and effectiveness in our core activities. Further information is available in a press release published on 5 October 2009.

New public website (in early 2010)

A further, major initiative they are undertaking as part of our efforts to improve our communications is to completely redesign there public website (currently at  www.emea.europa.eu). Scheduled for launch in early 2010, their new website will offer much-improved navigation and search functionality, and content will be structured more logically and intuitively. It will also be compliant with their new visual identity. In designing the new website, they have carefully considered the feedback they have received from you, their partners and stakeholders, through surveys and other channels over the past two years. Thanks to your input, they are confident that their  redesigned website will overcome many of the weaknesses identified with the current site, and will offer a greatly improved user-experience for all Agency audiences.
Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free.

As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.

Turn your Business Into an Investor Magnet

How to Write a Business Plan – Free E-Course

Get the secrets that turns your project into an investment magnet, 100% of our clients raise the finance they need to take their projects to the next stage, we will share these secrets with you. – Sign up for Free

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”